Febuxostat Compared with Allopurinol in Patients With Hyperuricemia and Gout

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Yearbook of Pediatrics

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0084-3954(08)70273-2
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Acute arsenic poisoning.

  2005cited by this paper
• Febuxostat compared with allopurinol in patients with hyperuricemia and gout.

  2005cited by this paper

• Febuxostat Improves MASLD in Male Rats: Roles of XOR Inhibition and Associated JNK/NRF2/HO-1 Pathway Changes

  2026cites this paper
• Ask an expert: Gout

  2026cites this paper
• Antioxidant Activity of Hydroxyquinolone Derivatives: Experimental, Computational, Hirshfeld Surface, and ADMET Analyses

  2026cites this paper
• The future of hyperuricemia management: integrating recombinant uricase and mRNA therapeutics.

  2026cites this paper
• Current state-of-the-art imaging of gout – A narrative review

  2026cites this paper
• Comparative efficacy and safety of febuxostat and allopurinol in chronic kidney disease stage 3–5 patients with asymptomatic hyperuricemia: a network meta-analysis

  2025cites this paper
• Febuxostat-induced hepatocellular injury

  2025cites this paper
• New drugs and their performance 10 years after approval: a systematic analysis

  2025cites this paper
• Inhibition of xanthine oxidoreductase with febuxostat, but not allopurinol, prevents inflammasome assembly and IL-1β release

  2025cites this paper
• Comparative Cardiovascular Safety of Nonsteroidal Anti‐Inflammatory Drug Versus Colchicine Use When Initiating Urate‐Lowering Therapy Among Patients With Gout: Target Trial Emulations

  2025cites this paper
• Allopurinol use and risk of acute coronary syndrome in gout patients: a population-based cohort study in Sweden

  2025cites this paper
• Changes in Practitioners’ Attitudes toward the Recommendations for Clinical Questions of the Japanese Guideline for Management of Hyperuricemia and Gout, Third Edition between 2018 and 2020 in the Questionnaire’s Surveys: Involving Their Attitude toward the New Questionnaires in 2020

  2025cites this paper
• Hepatic Safety of Febuxostat and Allopurinol in Gout Patients: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials

  2025influential citation
• Cardiovascular and Metabolic Effects of Febuxostat in Patients with Stage 3–4 Chronic Kidney Disease and Asymptomatic Hyperuricemia: A Prospective Observational Study

  2025cites this paper
• Bioequivalence evaluation of generic febuxostat versus Feburic® in healthy Chinese subjects: a randomized crossover study

  2025cites this paper
• A phase 1/2 pilot study of acupuncture and moxibustion at Zusanli (ST36) as a prophylactic treatment in middle-aged and elderly individuals

  2025cites this paper
• Data collaboration for causal inference from limited medical testing and medication data

  2025cites this paper
• The efficacy and safety of different doses of febuxostat and allopurinol: A meta-analysis

  2025influential citation
• Improvements in Health‐Related Quality of Life With Treat‐to‐Target Urate‐Lowering Therapy in Gout: A Post Hoc Analysis of a Randomized Multicenter Trial

  2025cites this paper
• Nanocarrier-Based Approach: Solid Lipid Nanoparticles for the Enhanced Bioavailability of Febuxostat

  2025cites this paper
• Efficacy and safety of epaminurad, a potent hURAT1 inhibitor, in patients with gout: a randomized, placebo-controlled, dose-finding study

  2025cites this paper
• Febuxostat versus allopurinol for renoprotection; a mini-review on recent concepts

  2025cites this paper
• Simultaneous determination of lesinurad and febuxostat in commercial fixed-dose combinations using a greener normal-phase HPTLC method

  2024cites this paper
• What Is Allopurinol Failure and What Should We Do About It?

  2024cites this paper
• Oral Dissolution Therapy of Uric Acid Stones: A Systematic Review

  2024cites this paper
• A stability-indicating liquid chromatography - diode array detection method for quantification of febuxostat in pharmaceuticals: a recent application to chemometrics based method development and comparative greenness assessment

  2024cites this paper
• Effect of uric acid reduction on chronic kidney disease. Systematic review and meta-analysis

  2024cites this paper
• A content analysis of medication adherence material in patient educational resources about gout

  2024cites this paper
• Uric acid-lowering effect of harpagoside and its protective effect against hyperuricemia-induced renal injury in mice.

  2024cites this paper
• Hyperuricemia and intravenous fat emulsion are risk factors for gout flares during active gastrointestinal bleeding: a case control study

  2024cites this paper
• Treatment efficacy of febuxostat compared with allopurinol in hyperuricemia patients with hypertensive: A randomized, single-blind controlled trial

  2024influential citation
• Toward a holistic tophus assessment in gout clinical trials: What lies beyond tophus count and size?

  2024cites this paper
• Uric acid in health and disease: From physiological function to pathogenic mechanism.

  2024cites this paper
• Comparative Risk of Gout Flares When Initiating or Escalating Various Urate‐Lowering Therapy: A Systematic Review With Network Meta‐Analysis

  2024influential citation
• Combination Treatment with Verinurad and Allopurinol in CKD

  2024cites this paper
• Cardiovascular safety of febuxostat versus allopurinol among the Asian patients with or without gout: A systematic review and meta‐analysis

  2024cites this paper
• Comparison of Gout Flares With the Initiation of Treat‐to‐Target Allopurinol and Febuxostat: A Post‐Hoc Analysis of a Randomized Multicenter Trial

  2024cites this paper
• Yet More Reassurance: Treat-to-Target With Allopurinol or Febuxostat is Safe and Effective in Lowering Serum Urate in People With CKD.

  2024cites this paper
• "Targeting Protein Receptors and Enzymes for Precision Management of Urolithiasis: A Comprehensive Review.

  2024cites this paper
• Efficacy and safety of the urate-lowering agent febuxostat in chronic heart failure patients with hyperuricemia: results from the LEAF-CHF study

  2024cites this paper
• Predictors of Inadequate Serum Urate Response to Low-Dose Febuxostat in Male Patients with Gout

  2024cites this paper
• Gout: global epidemiology, risk factors, comorbidities and complications: a narrative review

  2024cites this paper
• Efficacy and Safety of Different Doses of Urico-Lowering Agents in The Treatment of Gout with Hyperuricemia: A Systematic Review and Network Meta-Analysis

  2024cites this paper
• Post-hoc analysis of two gout remission definitions in a two-year randomized controlled trial of nurse-led versus usual gout care.

  2024cites this paper
• Hyperuricemia and its related diseases: mechanisms and advances in therapy

  2024cites this paper
• Efficacy and Safety of Allopurinol and Febuxostat in Patients With Gout and CKD: Subgroup Analysis of the STOP Gout Trial.

  2024cites this paper
• Asymptomatic hyperuricemia: to treat or not a threat? A clinical and evidence-based approach to the management of hyperuricemia in the context of cardiovascular diseases.

  2024cites this paper
• Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial

  2024cites this paper
• Anti-Hyperuricemic Effects of Extracts from Chaenomeles speciosa (Sweet) Nakai Fruits on Hyperuricemic Rats

  2024cites this paper
• Identification of inhibitors from a functional food-based plant Perillae Folium against hyperuricemia via metabolomics profiling, network pharmacology and all-atom molecular dynamics simulations

  2024cites this paper
• Ameliorative action of “daitongxiao” against hyperuricemia includes the “uric acid transporter group”

  2024cites this paper
• Comprehensive Analysis of Therapeutic Strategies for Gouty Nephropathy: Insights from Clinical Trials.

  2024cites this paper
• Moving urate-lowering therapy in gout beyond guideline recommendations.

  2024cites this paper
• Bioassay-Guided Isolation and Identification of Xanthine Oxidase Inhibitory Constituents from the Fruits of Chaenomeles speciosa (Sweet) Nakai

  2024cites this paper
• Gout Flares After Stopping Anti‐Inflammatory Prophylaxis: A Rapid Literature Review and Meta‐Analysis

  2024cites this paper
• The Stiff Joint: Comparative Evaluation of Monotherapy and Combination Therapy With Urate Lowering Agents in Managing Acute Gout

  2023cites this paper
• Preparation of chitosan-coated hollow tin dioxide nanoparticles and their application in improving the oral bioavailability of febuxostat

  2023cites this paper
• In vivo study of newly developed albumin-conjugated urate oxidase for gout treatment

  2023cites this paper
• Effect of Febuxostat versus Allopurinol on the Glomerular Filtration Rate and Hyperuricemia in Patients with Chronic Kidney Disease

  2023cites this paper
• Efficacy of dotinurad in patients with severe renal dysfunction

  2023influential citation
• Cardiovascular Safety of Febuxostat in Patients With Gout or Hyperuricemia

  2023cites this paper
• Hepatic Safety of Febuxostat and Allopurinol for Gout Patients: A Systematic Review of Randomized Controlled Trial

  2023cites this paper
• Expert consensus for the diagnosis and treatment of patients with hyperuricemia and high cardiovascular risk: 2023 update

  2023cites this paper
• Is colchicine prophylaxis required with start-low go-slow allopurinol dose escalation in gout? A non-inferiority randomised double-blind placebo-controlled trial

  2023cites this paper
• The Efficacy and Safety of Different Doses of Febuxostat Versus Allopurinol in the Treatment of Gout: A Meta-Analysis

  2023cites this paper
• Cardiovascular safety of xanthine oxidase inhibitors: an optimistic and unfinished story

  2023cites this paper
• Uric acid–reducing efficacy of Plectranthus amboinicus (Lour.) Spreng in mice with potassium oxonate-induced hyperuricemia

  2023cites this paper
• Gout and Cardiovascular Disease: Mechanisms, Risk Estimations, and the Impact of Therapies

  2023influential citation
• Dispelling Dampness, Relieving Turbidity and Dredging Collaterals Decoction, Attenuates Potassium Oxonate-Induced Hyperuricemia in Rat Models

  2023cites this paper
• Comparison between the Effects of Allopurinol and Febuxostat on the Survival of Patients on Maintenance Hemodialysis

  2023cites this paper
• Recent advances on the biological activities of purple sweet potato anthocyanins

  2023cites this paper
• Gout Flares and Mortality After Sodium-Glucose Cotransporter-2 Inhibitor Treatment for Gout and Type 2 Diabetes

  2023cites this paper
• Dietary supplements and medicinal plants in urolithiasis: diet, prevention, and cure.

  2023cites this paper
• History of Treatments Used to Treat Gout and Hyperuricemia

  2023cites this paper
• Towards a more ambitious uricemia target to improve joint and cardiovascular outcomes in gout

  2023cites this paper
• Females present higher dose‐adjusted drug concentrations of metoprolol and allopurinol/oxypurinol than males

  2023cites this paper
• Comparative Safety of Gout Treatment Strategies on Cardiovascular Outcomes Using Observational Data: Clone-censor-weight Target Trial Emulation Approach

  2023cites this paper
• Crystal Clear? The 2022 NICE Guideline for the Diagnosis and Management of Gout

  2023cites this paper
• Using linear regression model to explore the relationship between testosterone and SUA in adult males: NHANES 2013–2016

  2023cites this paper
• Computational Insights into the Inhibition Mechanism of Xanthine Oxidoreductase by Oxipurinol

  2023cites this paper
• Risk factors and management of hyperuricemia after renal transplantation

  2023cites this paper
• The Hong Kong Society of Rheumatology consensus recommendations for the management of gout

  2023cites this paper
• Epidemiology and treatment-related concerns of gout and hyperuricemia in Korean

  2023cites this paper
• Serum Urate–Lowering Efficacy and Safety of Tigulixostat in Gout Patients With Hyperuricemia: A Randomized, Double‐Blind, Placebo‐Controlled, Dose‐Finding Trial

  2023influential citation
• A follow‐up study to explore factors associated with rapid kidney function decline and new‐onset kidney disease among Chinese elderly population

  2022cites this paper
• Probiotic Limosilactobacillus fermentum GR-3 ameliorates human hyperuricemia via degrading and promoting excretion of uric acid

  2022cites this paper
• Review of Urate-Lowering Therapeutics: From the Past to the Future

  2022cites this paper
• Cardiovascular safety associated with febuxostat versus allopurinol among patients with gout: Update with accumulated use of febuxostat.

  2022cites this paper
• Treatment Guidelines in Gout.

  2022cites this paper
• Cardiovascular safety of febuxostat and allopurinol in patients with gout: A meta-analysis

  2022cites this paper
• Separation, identification and docking analysis of xanthine oxidase inhibitory peptides from pacific cod bone-flesh mixture

  2022cites this paper
• Febuxostat Protects Human Aortic Valve Endothelial Cells From Oxidized Low-density Lipoprotein–Induced Injury and Monocyte Attachment

  2022cites this paper
• Protective effects of corni fructus extract in mice with potassium oxonate–induced hyperuricemia

  2022cites this paper
• Solubility and Thermodynamic Data of Febuxostat in Various Mono Solvents at Different Temperatures

  2022cites this paper
• Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.

  2022cites this paper
• Population pharmacokinetic modelling of febuxostat in healthy subjects and people with gout

  2022cites this paper
• Increased risk of cardiovascular events and death in the initial phase after discontinuation of febuxostat or allopurinol: another story of the CARES trial

  2022cites this paper
• Hypouricemic and nephroprotective effects of palmatine from Cortex Phellodendri Amurensis: A uric acid modulator targeting Keap1-Nrf2/NLRP3 axis.

  2022cites this paper
• Current state and prospects of gout treatment in Korea

  2022cites this paper
• Simulation of febuxostat pharmacokinetics in healthy subjects and patients with impaired kidney function using physiologically based pharmacokinetic modeling

  2022cites this paper